Dynamic Adaptation of Tumor Immune Response with Nivolumab Demonstrated by 18F-FDG PET/CT

Naghmehossadat Eshghi, Tamara F. Lundeen, Phillip H Kuo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.

Original languageEnglish (US)
Pages (from-to)114-116
Number of pages3
JournalClinical Nuclear Medicine
Volume43
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Fluorodeoxyglucose F18
Immunotherapy
Neoplasms
Thorax
Adrenal Glands
Skeleton
Disease Progression
Immune System
Neoplasm Metastasis
nivolumab
Liver
Lymphadenopathy
Therapeutics

Keywords

  • flourodeoxyglucose
  • immunotherapy
  • lung cancer
  • nivolumab
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Dynamic Adaptation of Tumor Immune Response with Nivolumab Demonstrated by 18F-FDG PET/CT. / Eshghi, Naghmehossadat; Lundeen, Tamara F.; Kuo, Phillip H.

In: Clinical Nuclear Medicine, Vol. 43, No. 2, 01.02.2018, p. 114-116.

Research output: Contribution to journalArticle

Eshghi, Naghmehossadat ; Lundeen, Tamara F. ; Kuo, Phillip H. / Dynamic Adaptation of Tumor Immune Response with Nivolumab Demonstrated by 18F-FDG PET/CT. In: Clinical Nuclear Medicine. 2018 ; Vol. 43, No. 2. pp. 114-116.
@article{b44ceef99fdc49418f0f4f483cc73c93,
title = "Dynamic Adaptation of Tumor Immune Response with Nivolumab Demonstrated by 18F-FDG PET/CT",
abstract = "A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.",
keywords = "flourodeoxyglucose, immunotherapy, lung cancer, nivolumab, PET/CT",
author = "Naghmehossadat Eshghi and Lundeen, {Tamara F.} and Kuo, {Phillip H}",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/RLU.0000000000001934",
language = "English (US)",
volume = "43",
pages = "114--116",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Dynamic Adaptation of Tumor Immune Response with Nivolumab Demonstrated by 18F-FDG PET/CT

AU - Eshghi, Naghmehossadat

AU - Lundeen, Tamara F.

AU - Kuo, Phillip H

PY - 2018/2/1

Y1 - 2018/2/1

N2 - A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.

AB - A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.

KW - flourodeoxyglucose

KW - immunotherapy

KW - lung cancer

KW - nivolumab

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85040763782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040763782&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001934

DO - 10.1097/RLU.0000000000001934

M3 - Article

VL - 43

SP - 114

EP - 116

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 2

ER -